ArticleFrontiers in oncology2026
Clear cell renal cell carcinoma combined with intravascular large B-cell lymphoma: a case report and review of the literature.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) combined with intravascular large B-cell lymphoma (IVLBCL) is an extremely rare collision tumor, and its coexistence is often missed or misdiagnosed, making clinical diagnosis and treatment notably difficult. Case demonstration: We present the case of a 68-year-old male, in whom imaging revealed a nodular soft tissue density shadow in the parenchyma of the left kidney. Immunohistochemistry and molecular testing confirmed the combination of ccRCC and IVLBCL. Following surgery, the patient underwent comprehensive examinations, including bone marrow biopsy and cytology, to rule out systemic lymphoma involving the kidneys. The patient received postoperative chemotherapy and was still in a favorable condition after 16 months of follow-up. Conclusion: In the ccRCC combined with IVLBCL, the lymphoma component is confined within the blood vessels of the RCC, making it extremely prone to misdiagnosis, which can lead to a poor prognosis. This case report presents an incidental finding of ccRCC combined with IVLBCL, aiming to raise physician awareness and provide valuable clinical references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.